Research

Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus

Marc Mendelson, Zunaid Barday, Roland Eastman, David Le Feuvre, Sally Candy, Hue-Tsi Wu, Charles Swanepoel

Abstract


Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance. We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus.

Authors' affiliations

Marc Mendelson, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, Cape Town

Zunaid Barday, Division of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital, Cape Town

Roland Eastman, Division of Neurology, Department of Medicine, Groote Schuur Hospital, Cape Town

David Le Feuvre, Department of Neurosurgery, Groote Schuur Hospital, Cape Town

Sally Candy, Department of Radiology, Groote Schuur Hospital, Cape Town

Hue-Tsi Wu, Division of Anatomical Pathology, National Health Laboratory Service, Cape Town

Charles Swanepoel, Division of Nephrology and Hypertension, Department of Medicine, Groote Schuur Hospital, Cape Town

Full Text

PDF (505KB) HTML

Keywords

Post-transplant lymphoproliferative disease; Epstein-Barr Virus; Sirolimus

Cite this article

South African Medical Journal 2012;102(12):924-926. DOI:10.7196/SAMJ.5500

Article History

Date submitted: 2011-12-01
Date published: 2012-08-24

Article Views

Abstract views: 2735
Full text views: 3714

Comments on this article

*Read our policy for posting comments here